Key result
Levosimendan is most widely indicated for decompensated heart failure patients on beta-blockers, but has not demonstrated clear overall survival superiority compared to other inotropes in well-designed trials.
Why the study?
Levosimendan has not demonstrated clear superiority to other inotropes in well-designed trials, prompting a review of published studies to reach a consensus regarding its indications in cardiac patients.
Does levosimendan improve clinical outcomes in patients with cardiac conditions requiring inotropic support compared to standard inotropes or placebo?
Does levosimendan improve clinical outcomes in patients with cardiac conditions requiring inotropic support compared to standard inotropes or placebo?
Levosimendan is a valuable inotropic option for acute decompensated heart failure, particularly in patients on beta-blockers, and may aid in VA-ECMO weaning, though it lacks proven mortality benefits in several other critical care settings.
Supports selective levosimendan use in decompensated HF on beta-blockers; leaves open survival comparisons versus alternatives.
Levosimendan was maiden agent at the time of its emergence, promoting inotropy mainly through calcium sensitization of cardiac troponin C (cTnC). Levosimendan seems a lucrative option but has not demonstrated a clear superiority to other inotropes in well-designed trials. We searched the PubMed database and reviewed the pertinent studies published till 2021 and summarized various trials/studies to come to a consensus regarding its indications in cardiac patients. Patients with decompensated heart failure requiring inotropic support and receiving beta-blockers represent most widely accepted indication. Levosimendan infusions are increasingly used to facilitate extracorporeal membrane oxygenation (ECMO) weaning and avoiding hospitalizations in patients with end-stage heart failure. Levosimendan doesn’t seem to have long term survival benefit in ventricular dysfunction patients undergoing surgery. The evidence supporting the role in right ventricular failure is not well-established. These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2022) conducted a review in Cardiac conditions requiring inotropic support. Levosimendan vs. Placebo or standard inotropes (e.g., dobutamine, milrinone) was evaluated. Levosimendan is most widely indicated for decompensated heart failure patients on beta-blockers, but has not demonstrated clear overall survival superiority compared to other inotropes in well-designed trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: